These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29456021)

  • 1. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
    Becker I; Wang-Eckhardt L; Eckhardt M
    J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and Treatment of Canavan Disease.
    Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
    Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
    [No Abstract]   [Full Text] [Related]  

  • 8. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
    Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
    Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
    Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
    Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
    Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
    Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
    Baslow MH; Guilfoyle DN
    Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice.
    Hull V; Wang Y; Burns T; Zhang S; Sternbach S; McDonough J; Guo F; Pleasure D
    Ann Neurol; 2020 Mar; 87(3):480-485. PubMed ID: 31925837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
    Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
    Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice.
    Fröhlich D; Kalotay E; von Jonquieres G; Bongers A; Lee B; Suchowerska AK; Housley GD; Klugmann M
    Front Mol Neurosci; 2022; 15():1061257. PubMed ID: 36568275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
    Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
    J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ablating the Transporter Sodium-Dependent Dicarboxylate Transporter 3 Prevents Leukodystrophy in Canavan Disease Mice.
    Wang Y; Hull V; Sternbach S; Popovich B; Burns T; McDonough J; Guo F; Pleasure D
    Ann Neurol; 2021 Nov; 90(5):845-850. PubMed ID: 34498299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.